The study of safety and efficacy of YZJ-1139 in insomnia disorder

illustrative image

The company Shanghai Haiyan Pharmaceutical Technology Co., Ltd is enrolling patients into the clinical trial investigating Safety and Efficacy Study of YZJ-1139 in Insomnia Disorder.

The main purpose of this study is to assess efficacy and safety of YZJ-1139 in adult subjects with insomnia disorder. Efficacy will be evaluated on objective and subjective sleep parameters.

The study start date is December 17, 2021.

This page provides a more detailed overview of this clinical trial: https://ichgcp.net/clinical-trials-registry/NCT05525637.

Clinical Research News

Considerations for the Use of Real-World Data and Real-World Evidence To Support Regulatory Decision-Making for Drug and Biological Products
Submission of comments on ICH E6 (R3) Guideline for Good Clinical Practice(GCP) - Step 2b 
ICH E6(R3) Good Clinical Practice guidance - Step 2 Public Consultation
The study of the new investigational drug for acute myeloid leukemia and myelodysplastic syndrome
Open Label study of entrectinib in ROS1 gene fusion-positive rare adult, paediatric and teenage/young adult cancers
Gasherbrum Bio, Inc is starting the study of GSBR-1290 drug in overweight or obese healthy adults
A new study of Dexpramipexole in adolescents and adults with severe Eosinophilic Asthma

Prossimi studi clinici

The study of safety and efficacy of YZJ-1139 in insomnia disorder

All jobs

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi